The combination of a MEK inhibitor and the antidiabetic drug rosiglitazone was used to induce the transformation of invasive breast cancer cells in the EMT state into postmitotic adipocytes, thus preventing primary tumor invasion and metastasis formation (Ishay-Ronen et al., 2019). The gene discussed is MAP2K7; the disease is breast carcinoma.